Biomarkers and mediators of cardiovascular risk
Reunion Madeira 2015 Ticagrelor como antiagregante único en la angioplastia primaria
acs risk stratification and clinical management
Seminario 3
THE PROFILE OF THE HEART FAILURE PATIENT WHO DOESN’T BENEFIT FROM AN ICD Giosuè Mascioli, MD, FESC Humanitas Gavazzeni - Bergamo.
Www.metcardio.org When PCI in NSTEMI? Giuseppe Biondi Zoccai, MD Department of Medico-Surgical Sciences and Biotechnologies Sapienza University of Rome.
Examining the Science Underlying Myocardial Ischemia.
SWEDE HEART Prospective Registry based Randomized Clinical Trials (R-RCT) – a new concept for clinical research Lessons from the TASTE trial Stefan James,
Is heart failure associated with disability? European Academy for Medicine of Ageing, Martigny, January 24th 2013 Marius Myrstad.
Improving survival in symptomatic ischemic patients with left ventricular dysfunction Beneficial effects of long-term trimetazidine* therapy Fragasso G.
Structural and functional remodeling following pharmacologic intervention in volume overload heart failure Kristin Lewis, DVM Pathology Resident/Graduate.
Dr. Christos Toumpanakis MD PhD FRCP Consultant in Gastroenterology/Neuroendocrine Tumours Hon. Senior Lecturer University College of London Neuroendocrine.
